Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer
about
Localization and upregulation of survivin in cancer health disparities: a clinical perspectiveThe presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patientsFunctional characterization of novel mutations affecting survivin (BIRC5)-mediated therapy resistance in head and neck cancer patients.A texture based pattern recognition approach to distinguish melanoma from non-melanoma cells in histopathological tissue microarray sections.Human breast tissue disposition and bioactivity of limonene in women with early-stage breast cancer.Digital image analysis: a review of reproducibility, stability and basic requirements for optimal results.Prognostic value of survivin expression in breast cancer patients: a meta-analysis.Clinico-pathologic relevance of Survivin splice variant expression in cancerIncreased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients.Using Digital Quantification of Stained Tissue Microarrays as a Medium-Throughput, Quantitative Method for Measuring the Kinetics of Signal Transduction.The N-terminus of survivin is a mitochondrial-targeting sequence and Src regulatorRegulation of Apoptosis by HER2 in Breast Cancer.Controlled access of p53 to the nucleus regulates its proteasomal degradation by MDM2.Automated reagent-dispensing system for microfluidic cell biology assays.High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.Evaluation of survivin immunoexpression in the differentiation of high- and low-grade breast ductal carcinoma in situ.
P2860
Q26799719-6A2D67B9-C6FA-4F67-8DBA-A75CEF88233EQ34348172-802659A7-E96E-44D3-8BD9-391A3712A27FQ34480741-DFF5EDB7-C643-4630-BDAA-E1EC8CCC3008Q34729791-DBDFFDB0-6B09-44DD-A04E-0B7FDAA1973DQ36954979-D112E6E9-EC1F-446B-A292-663C1371D534Q37994831-CFBFACFE-AFAB-4852-88FB-F9352C0CAA03Q38108262-27368CBD-87F9-431A-9884-D2E431EDD683Q38116267-1DC7724B-0C71-4D1A-8FD6-96E5D9AB3879Q38801879-631EEFE4-878D-4905-848F-7C49AA01CB5EQ38968517-5A729A95-591C-42DC-B418-3FBA69B477CBQ39721066-C5CA2BBC-B3B9-41AC-A939-2080E3ABC81CQ39843650-CC966F3B-8567-4042-88D0-69498C544EB0Q40842578-7D233526-2E96-4DBB-A16F-7BDB734E4AE5Q44479490-FC96088D-9F9B-4112-ABA8-4362C6709294Q51311643-6DF7F525-7711-4A36-AB8F-5C1C4918C056Q55253587-FBB8FD82-F5F1-4F43-B0DC-B745EE5D4F2E
P2860
Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Validation of cytoplasmic-to-n ...... ved prognosis in breast cancer
@ast
Validation of cytoplasmic-to-n ...... ved prognosis in breast cancer
@en
type
label
Validation of cytoplasmic-to-n ...... ved prognosis in breast cancer
@ast
Validation of cytoplasmic-to-n ...... ved prognosis in breast cancer
@en
prefLabel
Validation of cytoplasmic-to-n ...... ved prognosis in breast cancer
@ast
Validation of cytoplasmic-to-n ...... ved prognosis in breast cancer
@en
P2093
P2860
P356
P1433
P1476
Validation of cytoplasmic-to-n ...... ved prognosis in breast cancer
@en
P2093
Donal J Brennan
Elton Rexhepaj
Goran Landberg
Karin Jirstrom
Michael J Duffy
Sallyann L O'Brien
P2860
P2888
P356
10.1186/1471-2407-10-639
P407
P577
2010-11-23T00:00:00Z
P5875
P6179
1042025000